Arca
Skip to content
Tools
Tools

80S Ribosome

Protein nucleic-acid complex in Homo sapiens that 9 drugs act on.

  • Drugs that act on it: 9
  • Approved: 1
  • In phases 1 to 3: 8
  • Sponsors: 5
  • Genes: 81

Who is on it, and how far along

Every drug ChEMBL records acting on FAU, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Antibody-drug conjugate 5
  • Other 2

Approved1

  • Ataluren

Phase 30

    Phase 28

    • Cycloheximide
    • Citatuzumab bogatox
    • Dorlimomab aritox
    • ELX-02
    • MT-3724
    • Taplitumomab paptox
    • Telimomab aritox
    • Zolimomab aritox

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Eloxx Pharmaceuticals, Inc.111%
      • Sesen Bio, Inc.111%
      • Tasly Tianjin Biopharmaceutical Co., Ltd.111%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 9 act as: 80S Ribosome inhibitor; the rest name their own mechanism.
      AtalurenApprovedPTC TherapeuticsSmall moleculeModulator80S Ribosome modulator1
      CycloheximidePhase 2—Small moleculeInhibitor2
      Citatuzumab bogatoxPhase 2Sesen Bio, Inc.Antibody-drug conjugateInhibitor0
      Dorlimomab aritoxPhase 2—Antibody-drug conjugateInhibitor0
      ELX-02Phase 2Eloxx Pharmaceuticals, Inc.OtherModulator80S Ribosome modulator0
      MT-3724Phase 2Molecular TemplatesOtherInhibitor0
      Taplitumomab paptoxPhase 2—Antibody-drug conjugateInhibitor0
      Telimomab aritoxPhase 2Tasly Tianjin Biopharmaceutical Co., Ltd.Antibody-drug conjugateInhibitor0
      Zolimomab aritoxPhase 2—Antibody-drug conjugateInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in ChildrenCycloheximide—Not yet recruitingSohag UniversitySep 3, 2026
      Clinical, Dermoscopic, and Mycological Evaluations of Resistant DermatophytosisCycloheximide—Not yet recruitingSohag UniversitySep 1, 2026
      Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyAtalurenPhase 1 / Phase 2RecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Jul 10, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3987582, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.